Oncotarget

Research Papers:

Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX

Theodore Vougiouklakis, Vassiliki Saloura, Jae-Hyun Park, Naofumi Takamatsu, Takashi Miyamoto, Yusuke Nakamura, _ Yo Matsuo

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2018; 9:31820-31831. https://doi.org/10.18632/oncotarget.25806

Metrics: HTML 2327 views  |   ?  


Abstract

Theodore Vougiouklakis1, Vassiliki Saloura1, Jae-Hyun Park1, Naofumi Takamatsu2, Takashi Miyamoto2, Yusuke Nakamura1,3 and Yo Matsuo2

1Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA

2OncoTherapy Science Inc., Kawasaki, Japan

3Department of Surgery, The University of Chicago, Chicago, IL, USA

Correspondence to:

Yusuke Nakamura, email: ynakamura@bsd.uchicago.edu

Yo Matsuo, email: y-matsuo@oncotherapy.co.jp

Keywords: methyltransferase; small-molecule inhibitor; SUV39H2; γ-H2AX

Received: May 05, 2018    Accepted: June 01, 2018    Published: August 07, 2018

ABSTRACT

Protein methyltransferase SUV39H2 was reported to methylate histone H2AX at lysine 134 and enhance the formation of phosphorylated H2AX (γ-H2AX), which causes chemoresistance of cancer cells. We found that a series of imidazo[1,2-a]pyridine compounds that we synthesized could inhibit SUV39H2 methyltransferase activity. One of the potent compounds, OTS193320, was further analyzed in in vitro studies. The compound decreased global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggered apoptotic cell death. Combination of OTS193320 with doxorubicin (DOX) resulted in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX. Further optimization of inhibitors and their in vivo analysis identified a compound, OTS186935, which revealed significant inhibition of tumor growth in mouse xenograft models using MDA-MB-231 breast cancer cells and A549 lung cancer cells without any detectable toxicity. Our results suggest that the SUV39H2 inhibitors sensitize cancer cells to DOX by reduction of γ-H2AX levels in cancer cells, and collectively demonstrate that SUV39H2 inhibition warrants further investigation as a novel anti-cancer therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25806